Correct management and low rate of contagiousness of healthcare workers in a University Hospital in Southern Italy: from contact tracing to serological investigation.
Adult
Antibodies, Viral
/ blood
Betacoronavirus
COVID-19
Contact Tracing
Coronavirus Infections
/ prevention & control
Female
Health Personnel
Hospitals, University
Humans
Male
Middle Aged
Occupational Exposure
Pandemics
/ prevention & control
Pneumonia, Viral
/ prevention & control
Practice Guidelines as Topic
SARS-CoV-2
Serologic Tests
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
20 07 2020
20 07 2020
Historique:
received:
01
07
2020
accepted:
01
07
2020
entrez:
24
7
2020
pubmed:
24
7
2020
medline:
13
8
2020
Statut:
epublish
Résumé
The COVID-19 epidemic, which began in Wuhan in December 2019, quickly spread all over the world, leading in a few months to a high number of deaths also in healthcare workers. The purpose of the study is to a) describe the importance of a correct management of SARS-CoV-2 infections; b) report the number of positive healthcare workers after the epidemic phase and to describe their socio-characteristics data, the main methods of transmission and the symptoms; c) to report the seroconversion rate of healthcare workers (HCWs). The study was conducted from March 9, 2020 to June 19, 2020 in three phases:1) in a first phase, we implemented the guidelines to be followed for patient care in our hospital; 2) in a second phase, we provided the epidemiological investigation/contact tracing of HCWs; 3) we collected swabs on all healthcare workers and we also performed serological investigation. The number of healthcare workers under surveillance is of 2611 subjects and, of these, only 0.65% contracted COVID-19. In particular, 70.6% of these have been infected in the healthcare setting, 11, 8% in the family and 17.6% returning from high risk areas. Ultimately, only 0.1% of HCWs dedicated to the treatment of COVID-19 patients contracted the infection (one was asymptomatic). Only 2% of HCWS were positive for serological investigation.
Identifiants
pubmed: 32701920
doi: 10.23750/abm.v91i9-S.10118
pmc: PMC8023094
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-86Références
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
J Infect Public Health. 2018 Jan - Feb;11(1):30-34
pubmed: 28285971
Ann Ig. 2018 Sep-Oct;30(5 Supple 2):86-98
pubmed: 30374514
Vaccine. 2014 Aug 27;32(38):4876-80
pubmed: 24161573
Am J Infect Control. 2016 Dec 1;44(12):1600-1605
pubmed: 27324612
J Prev Med Hyg. 2019 Mar 29;60(1):E12-E17
pubmed: 31041405
Cardiovasc Res. 2020 Oct 1;116(12):1932-1936
pubmed: 32267499
Euro Surveill. 2020 Mar;25(11):
pubmed: 32209163
Vaccines (Basel). 2019 Nov 03;7(4):
pubmed: 31684158
Leg Med (Tokyo). 2019 Feb;36:73-80
pubmed: 30419494
Am J Infect Control. 2014 Mar;42(3):316-20
pubmed: 24581020
Acta Biomed. 2020 Apr 10;91(3-S):175-179
pubmed: 32275287
Lancet Infect Dis. 2020 Jul;20(7):809-815
pubmed: 32330439
Clin Microbiol Infect. 2020 Jul;26(7):954-956
pubmed: 32229288
Lancet Respir Med. 2020 Mar;8(3):e13
pubmed: 32061333
J Public Health Policy. 2020 Sep;41(3):238-244
pubmed: 32472024
Emerg Infect Dis. 2005 Jul;11(7):1142-5
pubmed: 16022801
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Early Hum Dev. 2020 May;144:105026
pubmed: 32247898
Epidemiol Rev. 2019 Jan 31;41(1):69-81
pubmed: 31781765
Euro Surveill. 2020 Feb;25(6):
pubmed: 32046815
Am J Forensic Med Pathol. 2015 Jun;36(2):88-90
pubmed: 25899030
Euro Surveill. 2020 Mar;25(9):
pubmed: 32156327
Lancet Public Health. 2020 Jun;5(6):e310
pubmed: 32339478
Ann Ig. 2019 Mar-Apr;31(2 Supple 1):13-24
pubmed: 30994160
Acta Biomed. 2019 Sep 13;90(9-S):45-53
pubmed: 31517889
Intern Emerg Med. 2013 Dec;8(8):717-23
pubmed: 22249916
New Microbiol. 2018 Jan;41(1):42-46
pubmed: 29313864
Ann Ig. 2016 Sep-Oct;28(5):360-6
pubmed: 27627667